[HTML][HTML] 中西医结合治疗非小细胞肺癌研究进展
叶俊宏， 文曦儿， 陈立义， 林嘉豪， 陈小鑫… - Traditional Chinese …, 2018 - hanspub.org
… Chinese and Western medicine to treat non-small-cell lung cancer. … 瑞沙(Iressa)和埃罗替
尼(Erlotinib)等.② 作用于血管生成的靶向药物,例子有贝伐单抗(Bevacizumab).③ 多靶点治疗药物,…
尼(Erlotinib)等.② 作用于血管生成的靶向药物,例子有贝伐单抗(Bevacizumab).③ 多靶点治疗药物,…
[HTML][HTML] 奥希替尼联合贝伐珠单抗在获得性EGFR T790M 突变晚期非小细胞肺癌的疗效分析
顾艳斐， 田笑如， 王若天， 李小雪， 钱坤… - … of Lung Cancer, 2022 - ncbi.nlm.nih.gov
… 突变非小细胞肺癌（non-small cell lung cancer, NSCLC）有效的第三… , osimertinib plus
bevacizumab combination failed to show … bevacizumab to osimertinib could not show advantages …
bevacizumab combination failed to show … bevacizumab to osimertinib could not show advantages …
[HTML][HTML] EGFR 敏感突变NSCLC 患者的最佳治疗模式探讨
史钟， 范云 - Chinese Journal of Lung Cancer, 2015 - ncbi.nlm.nih.gov
… 应用于非小细胞肺癌（non-small cell lung cancer, NSCLC）患者，但… have made a
summary on the current therapeutic models of EGFR-TKI combined with chemotherapy/bevacizumab …
summary on the current therapeutic models of EGFR-TKI combined with chemotherapy/bevacizumab …
[HTML][HTML] PD⁃ 1/PD⁃ L1 免疫检查点抑制剂在肺癌临床研究中的进展
王梦玮， 徐天蔚， 王朝霞 - 南京医科大学学报(自然科学版), 2021 - jnmu.njmu.edu.cn
… alone or with bevacizumab for non⁃small⁃cell lung cancer[J].… in combination with ipilimumab
in small⁃cell lung cancer[J].… of non⁃small cell lung cancer or small cell lung cancer. This …
in small⁃cell lung cancer[J].… of non⁃small cell lung cancer or small cell lung cancer. This …
[HTML][HTML] Pan-negative 型非小细胞肺癌的研究进展
孙丽， 熊志成， 韩琤波 - Chinese Journal of Lung Cancer, 2018 - ncbi.nlm.nih.gov
… so on, have been found in non-small cell lung cancer (NSCLC) … Targeted drugs bring benefits
for these NSCLC patients with … bevacizumab, with or without atezolizumab in 1L non-small …
for these NSCLC patients with … bevacizumab, with or without atezolizumab in 1L non-small …
[HTML][HTML] 免疫检查点抑制剂在驱动基因阳性晚期非小细胞肺癌中的应用进展
张同梅， 李宝兰 - Chinese Journal of Lung Cancer, 2021 - ncbi.nlm.nih.gov
… of patients in advanced non-small cell lung cancer (NSCLC) … More and more studies have
shown that ICIs can also benefit … +platinum+bevacizumab+salvage SBRT Ⅱ Not yet recruiting …
shown that ICIs can also benefit … +platinum+bevacizumab+salvage SBRT Ⅱ Not yet recruiting …
[HTML][HTML] 非小细胞肺癌腹膜转移预后因素的单中心回顾性分析
曹宝山， 刘燕娥， 尹文琤， 李倩， 梁莉 - … Journal of Lung Cancer, 2019 - ncbi.nlm.nih.gov
… 本研究旨在探讨非小细胞肺癌（non-small cell lung cancer, NSCLC）PC的临床病理特征和治疗
… for lung cancer with PC is encouraged when possible. More patients with PC may benefit …
… for lung cancer with PC is encouraged when possible. More patients with PC may benefit …
[HTML][HTML] 罕见CRISPLD2-NRG1 融合突变晚期混合型非小细胞肺癌1 例并文献复习
C Chunmei, YU Yang, H Meijuan - … Journal of Lung Cancer, 2024 - ncbi.nlm.nih.gov
… The NCCN clinical practic guidlines in oncology for non-small cell lung cancer (version 3.
2023). https://www.nccn.org/guidelines/guidelines-detail category=1＆id=1450.https://www.…
2023). https://www.nccn.org/guidelines/guidelines-detail category=1＆id=1450.https://www.…
[HTML][HTML] 免疫治疗在EGFR 突变晚期非小细胞肺癌中的研究进展
LIU Yaoyao, M Jianlong - Chinese Journal of Lung Cancer, 2023 - ncbi.nlm.nih.gov
… without driver mutation, clinical benefits of these agents are … 为非小细胞肺癌（non-small cell
lung cancer, NSCLC）中首个可… 临床前研究 [23] 表明，与未接受厄洛替尼（Erlotinib）治疗的诱导…
lung cancer, NSCLC）中首个可… 临床前研究 [23] 表明，与未接受厄洛替尼（Erlotinib）治疗的诱导…
[HTML][HTML] 敏感驱动基因阳性非小细胞肺癌脑膜转移药物治疗的管理
陆志琴， 蔡婧， 曾治民， 刘安文 - Chinese Journal of Lung Cancer, 2020 - ncbi.nlm.nih.gov
… 脑膜转移（leptomeningeal metastasis, LM）是晚期非小细胞肺癌（non-small cell lung cancer,
NSCLC）严重并发症之一，虽然发生率不高，但临床症状表现严重，预后差。驱动基因阳性NSCLC…
NSCLC）严重并发症之一，虽然发生率不高，但临床症状表现严重，预后差。驱动基因阳性NSCLC…